{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:48:38Z","timestamp":1782409718606,"version":"3.54.5"},"reference-count":24,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100012155","name":"Channel 7 Telethon Trust","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100012155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2026,6,3]]},"DOI":"10.1136\/ejhpharm-2026-004995","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:25:16Z","timestamp":1782408316000},"page":"ejhpharm-2026-004995","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Chemical and visual compatibility of dexmedetomidine injection with parenteral medications used in neonatal intensive care settings"],"prefix":"10.1136","author":[{"given":"D Thisuri N","family":"De Silva","sequence":"first","affiliation":[{"name":"Curtin Medical School, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Curtin Medical School, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Strunk","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre for Vaccines and Infectious Diseases, The University of Western Australia, Perth, Western Australia, Australia"},{"name":"Neonatology, King Edward Memorial Hospital for Women Perth, Subiaco, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabeelah","family":"Mukadam","sequence":"additional","affiliation":[{"name":"Pharmacy Department, King Edward Memorial Hospital for Women Perth, Subiaco, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Petrovski","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3850-1778","authenticated-orcid":false,"given":"Kevin T","family":"Batty","sequence":"additional","affiliation":[{"name":"Curtin Medical School, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2026062510251207000_ejhpharm-2026-004995v1.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2024-003004","article-title":"Dexmedetomidine in neonates: utilisation trends and safety profile over time in a neonatal intensive care unit","volume":"9","author":"Kayki","year":"2025","journal-title":"BMJ Paediatr Open"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.2","article-title":"Dexmedetomidine: An Alternative to Pain Treatment in Neonatology","volume":"10","author":"Mantec\u00f3n-Fern\u00e1ndez","year":"2023","journal-title":"Children (Basel)"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41372-022-01351-3","article-title":"Dexmedetomidine - An emerging option for sedation in neonatal patients","volume":"42","author":"McDonald","year":"2022","journal-title":"J Perinatol"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.4","unstructured":"ASHP . ASHP Injectable Drug Information: A Comprehensive Guide to Compatibility and Stability. Bethesda (MD): American Society of Health-System Pharmacists, 2025."},{"key":"2026062510251207000_ejhpharm-2026-004995v1.5","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304887"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.6","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.174268"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.7","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-018-0265-7","article-title":"Potential drug incompatibilities in the neonatal intensive care unit: a network analysis approach","volume":"19","author":"Leopoldino","year":"2018","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.8","first-page":"230","article-title":"Compatibility screening of precedex during simulated y-site administration with other drugs","volume":"6","author":"Trissel","year":"2002","journal-title":"Int J Pharm Compd"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jpen.2469","article-title":"Physical compatibility of medications with concentrated neonatal and pediatric parenteral nutrition: A simulated Y-site drug compatibility study","volume":"47","author":"Ross","year":"2023","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.10","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ncp.10391","article-title":"Physicochemical Compatibility of Dexmedetomidine With Parenteral Nutrition","volume":"35","author":"Campos-Baeta","year":"2020","journal-title":"Nutr Clin Pract"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.11","first-page":"796","article-title":"Stability indicating HPLC method validation for the assay of dexmedetomidine in dexmedetomidine hydrochloride injection","volume":"3","author":"Krishna","year":"2015","journal-title":"Int J Chem Pharm Anal"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.12","unstructured":"European Medicines Agency . ICH Q2(R2) Guideline on validation of analytical procedures EMA\/CHMP\/ICH\/82072\/2006. 2023."},{"key":"2026062510251207000_ejhpharm-2026-004995v1.13","first-page":"939","article-title":"Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets","volume":"34","author":"Allen","year":"1977","journal-title":"Am J Hosp Pharm"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.14","first-page":"2359","article-title":"Physical compatibility of melphalan with selected drugs during simulated Y-site administration","volume":"50","author":"Trissel","year":"1993","journal-title":"Am J Hosp Pharm"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.15","first-page":"233","article-title":"Physical Compatibility of Alprostadil with Commonly Used IV Solutions and Medications in the Neonatal Intensive Care Unit","volume":"11","author":"Dice","year":"2006","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00431-020-03854-7","article-title":"Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units","volume":"180","author":"De Basagoiti","year":"2021","journal-title":"Eur J Pediatr"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.17","doi-asserted-by":"crossref","first-page":"104043","DOI":"10.1016\/j.xphs.2025.104043","article-title":"Physicochemical compatibility of alprostadil injection with parenteral medications used in neonatal intensive care settings","volume":"115","author":"Hamilton","year":"2026","journal-title":"J Pharm Sci"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00228-024-03678-6","article-title":"Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings","volume":"80","author":"De Silva","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.19","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16030419","article-title":"The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings","volume":"16","author":"De Silva","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.20","unstructured":"United States Pharmacopeia and National Formulary. Rockville (MD) United States Pharmacopeial Convention; 2025."},{"key":"2026062510251207000_ejhpharm-2026-004995v1.21","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150853"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.22","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2012-000239"},{"key":"2026062510251207000_ejhpharm-2026-004995v1.23","unstructured":"O\u2019Donnell PB , Bokser AD . Stability of pharmaceutical products. In: Gerbino PP , ed. Remington: The Science and Practice of Pharmacy. 21st edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2006: 1025\u201336."},{"key":"2026062510251207000_ejhpharm-2026-004995v1.24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0018578719844168","article-title":"Compatibility of Y-Site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs","volume":"55","author":"Lessard","year":"2020","journal-title":"Hosp Pharm"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2026-004995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:25:22Z","timestamp":1782408322000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2026-004995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":24,"alternative-id":["10.1136\/ejhpharm-2026-004995"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2026-004995","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]}}}